US represented the world’s third largest diabetes patient pool with more than 27 Million diabetes patients in 2015. Projections from the report suggest that the US Diabetes Market is expected to grow at a CAGR of nearly 11% during 2016-2021, reaching revenues worth more than US$ 60 Billion by 2021.
A new report published by IMARC Group titled “US Diabetes Market Report: 2016 – 2020” provides a deep insight into the diabetes market in the US. The report finds that the US represented the world’s third largest diabetes patient pool with more than 27 Million diabetes patients in 2015. The study suggests that people who are obese, overweight or aged above 65 years are more prone to the risks of diabetes. As per IMARC Group estimates, more than half of the total US population is either obese or overweight which is mainly due to their sedentary lifestyles, lack of physical exercise and unhealthy dietary habits. Furthermore, the number of people aged 65 years and older have steadily increased in the US since the 1960’s. From around 9% of the total population in 1960, this age group accounted for nearly 15% of the entire US population in 2015. Driven by the rising prevalence of diabetes and the fact that the United States has one of the highest per capita healthcare expenditures, the market for diabetes drugs is expected to exhibit strong growth in the coming years. Projections from the report suggest that the diabetes drug market in the US is expected to grow at a CAGR of nearly 11% during 2016-2021, reaching revenues worth more than US$ 60 Billion by 2021.
Browse full report: http://www.imarcgroup.com/US-diabetes-market
The report provides population and prevalence rates of diabetes by type, region, gender and age group. Findings from the report suggest that Type-2 diabetes is more prevalent than Type-1 diabetes and currently accounts for the majority of all diagnosed cases of diabetes. In terms of regions, urban areas have a higher prevalence of diabetes as compared to rural areas. Based on gender, females currently account for the majority of the total diabetes patients. Based on age groups, the age group 40-59 currently accounts for the majority of the total diabetes patients in the US followed by the age group 60-79 and 20-39.
The report has also segmented the US diabetes market on the basis of drug types. The market currently consists of oral anti-diabetics and insulin with insulin accounting for the majority of the total sales. For each of the two drug types, the report also provides historical market trends, market breakup by class, key players and market outlook. Based on class, DPP-IV inhibitors represent the biggest class in the oral anti-diabetics market while long acting insulin represent the biggest class in the US insulin market.
This report provides an analytical and statistical insight into the US diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in the United States. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the US diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the US diabetes market in any form.
Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/
Follow us on twitter: @imarcglobal
For more information:
Last updated on: 07/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.